DRESS (drug reaction with eosinophilia and systemic symptoms) syndrome to voxelotor treatment of sickle cell disease
Sickle cell disease (SCD), an inherited disorder, leads to polymerization of hemoglobin and formation of sickle cells resulting in vaso-occlusive crises and chronic anemia.1 Although hydroxyurea is still the most commonly used treatment, new molecules are emerging to treat sickle cell patients.2 Vox...
Saved in:
Published in: | The journal of allergy and clinical immunology in practice (Cambridge, MA) Vol. 10; no. 12; pp. 3320 - 3322 |
---|---|
Main Authors: | , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
Elsevier Inc
01-12-2022
Elsevier Limited |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Sickle cell disease (SCD), an inherited disorder, leads to polymerization of hemoglobin and formation of sickle cells resulting in vaso-occlusive crises and chronic anemia.1 Although hydroxyurea is still the most commonly used treatment, new molecules are emerging to treat sickle cell patients.2 Voxelotor, was approved by the U.S. Food and Drug Administration for the SCD in 2019. Blood tests revealed lactatemia (4.5 mmol/L, N < 2.2), acute renal failure with increased creatinine level (713 μmol/L, N < 80; Figure 1, A) requiring extrarenal purification session, increased serum levels of alanine aminotransferase (×20 N), and intrahepatic cholestasis. Epstein-Barr virus, cytomegalovirus, parvovirus B19, and human herpes virus 6 blood serologies revealed an old contact, viral serologies (hepatitis B virus, hepatitis C virus, human immunodeficiency virus) as well as repeated blood cultures and antinuclear antibodies remained negative. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 2213-2198 2213-2201 |
DOI: | 10.1016/j.jaip.2022.08.046 |